Live feed18:15:00·1307dPRReleasevia QuantisnowOnce-Weekly TransCon™ CNP Achieved Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma's Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 YearsByQuantisnow·Wall Street's wire, on your screen.ASND· Ascendis Pharma A/SHealth Care
